12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter study designed to assess the safety of intranasal
administration of 400 μg of fluticasone propionate twice a day delivered by the OptiNose
device in subjects with chronic sinusitis with or without nasal polyps. The study consists of
an up-to-7-day pretreatment phase followed a 12-month open-label treatment phase. The
duration of each subject's participation is approximately 53 weeks.